Filtered By:
Vaccination: Cancer Vaccines

This page shows you your search results in order of date. This is page number 4.

Order by Relevance | Date

Total 243 results found since Jan 2013.

In vitro and in vivo Evidence on Intra-tumor Injection of Allogeneic Serum for Immunotherapy in a Mouse Model of Colon Cancer
Iran J Allergy Asthma Immunol. 2022 Oct 26;21(5):549-560. doi: 10.18502/ijaai.v21i5.11042.ABSTRACTIt is believed that preformed antibodies are responsible for blood transfusion reactions and transplant rejections. In order to remove a tumor, the tissue must be rejected. On the basis of transfusion reaction and transplantation immunology, we hypothesized that allogeneic serum can inhibit tumor growth when injected intra-tumor. Initially, an in vitro cytotoxicity test was conducted using the C57BL/6 serum (intact or decomplemented) in combination with the BALB/c-originating CT26 cell line. The CT26 cell line was used to esta...
Source: Iranian Journal of Allergy, Asthma and Immunology - November 7, 2022 Category: Allergy & Immunology Authors: Erfan Basirat Danial Dehghan Ardeshir Abbasi Nafiseh Pakravan Source Type: research

U.S. weighs crackdown on experiments that could make viruses more dangerous
.news-article__hero--featured .parallax__element{ object-position: 50% 40%; -o-object-position: 50% 40%; } .scroll-wrapper { overflow-x: auto; } .scroll-wrapper .news-article__figure__image{ width: 2680px; max-width: none; padding-bottom: .75rem; } .scroll-fade-before, .scroll-fade-after { position: absolute; width: 1.5rem; transition-duration: .1s; opacity: 1; } .scroll-fade-before { left: 1rem; /*margin-left: -1px;*/ background: linear-gradient(90deg, #fff, #fff 35%, hsla(0, 0%, 100%, 0)); } .scroll-fade-after { right: 1rem; /*margin-right: -1px;*/ background: linear-gradient(270deg, #fff, #fff 35%, hsla(0,...
Source: ScienceNOW - October 19, 2022 Category: Science Source Type: news

STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Through Four Years in Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final data from the long-term extension (LTE) of the Phase 3 UNIFI study demonstrating efficacy and safety of STELARA® (ustekinumab) through four years of treatment in adult patients with moderately to severely active ulcerative colitis (UC).1 Among all patients who had achieved clinical responsea with STELARA during induction, 64.9 percent were in symptomatic remissionb after 44 weeks of maintenance. At week 200 (four years), this proportion of patients was 55.2 percent; the majority (96.4 percen...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news

Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens
EBioMedicine. 2022 Sep 27;84:104271. doi: 10.1016/j.ebiom.2022.104271. Online ahead of print.ABSTRACTBACKGROUND: The identification of baseline host determinants that associate with robust HIV-1 vaccine-induced immune responses could aid HIV-1 vaccine development. We aimed to assess both the collective and relative performance of baseline characteristics in classifying individual participants in nine different Phase 1-2 HIV-1 vaccine clinical trials (26 vaccine regimens, conducted in Africa and in the Americas) as High HIV-1 vaccine responders.METHODS: This was a meta-analysis of individual participant data, with studies c...
Source: Cancer Control - September 30, 2022 Category: Cancer & Oncology Authors: Yunda Huang Yuanyuan Zhang Kelly E Seaton Stephen De Rosa Jack Heptinstall Lindsay N Carpp April Kaur Randhawa Lyle R McKinnon Paul McLaren Edna Viegas Glenda E Gray Gavin Churchyard Susan P Buchbinder Srilatha Edupuganti Linda-Gail Bekker Michael C Keefe Source Type: research

Virus-like particle vaccinology, from bench to bedside
Cell Mol Immunol. 2022 Aug 12. doi: 10.1038/s41423-022-00897-8. Online ahead of print.ABSTRACTVirus-like particles (VLPs) have become key tools in biology, medicine and even engineering. After their initial use to resolve viral structures at the atomic level, VLPs were rapidly harnessed to develop antiviral vaccines followed by their use as display platforms to generate any kind of vaccine. Most recently, VLPs have been employed as nanomachines to deliver pharmaceutically active products to specific sites and into specific cells in the body. Here, we focus on the use of VLPs for the development of vaccines with broad field...
Source: Cellular and Molecular Immunology - August 12, 2022 Category: Molecular Biology Authors: Mona O Mohsen Martin F Bachmann Source Type: research

STELARA ® (ustekinumab) Approved by the U.S. Food and Drug Administration to Treat Pediatric Patients with Active Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, August 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) for the treatment of pediatric patients six years of age and older with active psoriatic arthritis (PsA). This rare disease that resembles adult PsA affects five to eight percent of children and adolescents with chronic inflammatory arthritis.*1-7 Two of the four indications for STELARA now include pediatric patients, further expanding its treatment profile since the first approval in 2009 for adults living with moderate...
Source: Johnson and Johnson - August 1, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Why efforts to make better, more universal coronavirus vaccines are struggling
There’s a new call from the White House to develop vaccines that might protect against future SARS-CoV-2 mutants or even unknown coronaviruses. “The vaccines we have are terrific, but we can do better than terrific,” Ashish Jha, White House COVID-19 response coordinator, said at a vaccine summit yesterday that gathered researchers, companies, and government officials. “Ultimately, we need vaccines that can protect us no matter what Mother Nature throws at us.” But no specific funding request to Congress was revealed at the summit, or any concrete plans, so vaccine developers and the public shouldn’t expect...
Source: Science of Aging Knowledge Environment - July 27, 2022 Category: Geriatrics Source Type: research

Vaccines against SARS ‐CoV‐2 are safe to administer in patients with antibodies to pegaspargase
ConclusionSARS-CoV-2 vaccination is safe in this population.
Source: Cancer Medicine - July 15, 2022 Category: Cancer & Oncology Authors: Hope D. Swanson, Hana Hakim, Diego R. Hijano, Ted Morton, Shane Cross, Hiroto Inaba, Sima Jeha, Ching ‐Hon Pui, Seth E. Karol Tags: BRIEF COMMUNICATION Source Type: research

Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics
Curr Opin Chem Biol. 2022 Jul 1;70:102172. doi: 10.1016/j.cbpa.2022.102172. Online ahead of print.ABSTRACTUntil recently, the development of new human adjuvants was held back by a poor understanding of their mechanisms of action. The field was revolutionized by the discovery of the toll-like receptors (TLRs), innate immune receptors that directly or indirectly are responsible for detecting pathogen-associated molecular patterns (PAMPs) and respond to them by activating innate and adaptive immune pathways. Hundreds of ligands targeting various TLRs have since been identified and characterized as vaccine adjuvants. This work...
Source: Current Opinion in Chemical Biology - July 5, 2022 Category: Biochemistry Authors: Arshpreet Kaur Jeremy Baldwin Deshkanwar Brar Deepak B Salunke Nikolai Petrovsky Source Type: research

SARS-CoV-2 omicron: Light at the end of the long pandemic tunnel or another false dawn for immunodeficient patients?
J Allergy Clin Immunol Pract. 2022 Jun 22:S2213-2198(22)00597-9. doi: 10.1016/j.jaip.2022.06.011. Online ahead of print.ABSTRACTCOVID-19 has had a disastrous impact on the world. Apart from at least 6 million deaths, countless COVID-19 survivors are suffering long-term physical and psychiatric morbidity. Hundreds of millions have been plunged into poverty caused by economic misery, particularly in developing nations. Early in the pandemic, it became apparent certain groups of individuals such as the elderly and those with comorbidities were at increased risk of severe disease. In addition, patients with some forms of immun...
Source: Clinical Lung Cancer - June 25, 2022 Category: Cancer & Oncology Authors: Rohan Ameratunga Euphemia Leung See-Tarn Woon Lydia Chan Richard Steele Klaus Lehnert Hilary Longhurst Source Type: research

News at a glance: China ’s carbon pledge, ARPA-H’s interim head, and an exascale computer
Some content has been removed for formatting reasons. Please view the original article for the best reading experience. Table of contents A version of this story appeared in Science, Vol 376, Issue 6597. Download PDF CONSERVATION U.S. moves to stop Alaska copper mine The U.S. Environmental Protection Agency (EPA) is moving to block construction of a massive copper and gold mine that would risk polluting the headwaters of Alaska’s Bristol Bay, home to the world’s largest sockeye salmon runs. EPA announced last week it plans to forbid dis...
Source: Science of Aging Knowledge Environment - June 2, 2022 Category: Geriatrics Source Type: research

Predictors of seroconversion following COVID-19 vaccination
CONCLUSION: Vaccine responses vary by age and sex, with males showing lower rates of seroconversion as compared to females. Primary immunodeficiency along with active malignancy and ongoing immunosuppression with steroids and/or B-cell depletion therapy appeared to be the most common characteristics for those with lack of vaccine seroconversion following COVID-19 vaccination.PMID:35640775 | PMC:PMC9144839 | DOI:10.1016/j.anai.2022.05.026
Source: Annals of Allergy, Asthma and Immunology - May 31, 2022 Category: Allergy & Immunology Authors: Sergio E Chiarella Sarah M Jenkins Carin Y Smith Vikas Prasad Fnu Shakuntulla Vaibhav Ahluwalia Vivek N Iyer Elitza S Theel Avni Y Joshi Source Type: research